$660 Million is the total value of Soleus Capital Management, L.P.'s 65 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | New | SPDR SER TRput | $397,704,000 | – | 2,825,000 | +100.0% | 52.48% | – |
| BCAB | New | BIOATLA INC | $108,130,000 | – | 3,179,362 | +100.0% | 14.27% | – |
| GLTO | New | GALECTO INC | $18,923,000 | – | 1,512,648 | +100.0% | 2.50% | – |
| NVTA | New | INVITAE CORP | $10,233,000 | – | 244,760 | +100.0% | 1.35% | – |
| CCCC | New | C4 THERAPEUTICS INC | $8,897,000 | – | 268,548 | +100.0% | 1.17% | – |
| New | IONIS PHARMACEUTICALS INCnote 0.125%12/1 | $8,675,000 | – | 8,500,000 | +100.0% | 1.14% | – | |
| EXEL | New | EXELIXIS INC | $7,844,000 | – | 390,847 | +100.0% | 1.04% | – |
| New | DARIOHEALTH CORP | $5,739,000 | – | 401,606 | +100.0% | 0.76% | – | |
| SBTX | New | SILVERBACK THERAPEUTICS INC | $4,997,000 | – | 107,826 | +100.0% | 0.66% | – |
| VSPR | New | VESPER HEALTHCARE ACQSTN COR | $4,711,000 | – | 416,551 | +100.0% | 0.62% | – |
| OAC | New | OAKTREE ACQUISITION CORP | $4,111,000 | – | 281,565 | +100.0% | 0.54% | – |
| ESTA | New | ESTABLISHMENT LABS HLDGS INC | $2,519,000 | – | 66,921 | +100.0% | 0.33% | – |
| NEO | New | NEOGENOMICS INC | $2,474,000 | – | 45,951 | +100.0% | 0.33% | – |
| TPTX | New | TURNING POINT THERAPEUTICS I | $2,317,000 | – | 19,013 | +100.0% | 0.31% | – |
| ABBV | New | ABBVIE INC | $2,301,000 | – | 21,477 | +100.0% | 0.30% | – |
| ONCR | New | ONCORUS INC | $1,824,000 | – | 56,422 | +100.0% | 0.24% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $1,722,000 | – | 7,838 | +100.0% | 0.23% | – |
| MGEN | New | MIRAGEN THERAPEUTICS INC | $1,335,000 | – | 81,185 | +100.0% | 0.18% | – |
| SRRK | New | SCHOLAR ROCK HLDG CORP | $1,188,000 | – | 24,484 | +100.0% | 0.16% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $657,000 | – | 7,661 | +100.0% | 0.09% | – |
| KRYS | New | KRYSTAL BIOTECH INC | $625,000 | – | 10,423 | +100.0% | 0.08% | – |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $517,000 | – | 41,064 | +100.0% | 0.07% | – |
| OACWS | New | OAKTREE ACQUISITION CORP*w exp 99/99/999 | $358,000 | – | 91,793 | +100.0% | 0.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-04-29
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ESSA PHARMA INC | 16 | Q3 2023 | 10.8% |
| IRADIMED CORP | 16 | Q3 2023 | 5.8% |
| XENON PHARMACEUTICALS INC | 15 | Q3 2023 | 2.9% |
| IVERIC BIO INC | 14 | Q1 2023 | 6.5% |
| SURMODICS INC | 14 | Q3 2023 | 4.7% |
| NATERA INC | 13 | Q3 2023 | 3.9% |
| DEXCOM INC | 13 | Q2 2023 | 4.2% |
| NOVOCURE LTD | 13 | Q3 2023 | 3.4% |
| CRISPR THERAPEUTICS AG | 13 | Q2 2023 | 2.6% |
| LYRA THERAPEUTICS INC | 13 | Q3 2023 | 1.0% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.